Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

Bradley, 2015, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0 Bentzen, 2007, Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions, Nat Rev Clin Oncol, 4, 172, 10.1038/ncponc0744 Dai, 2015, Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer, Radiother Oncol, 114, 173, 10.1016/j.radonc.2014.12.009 Chinnaiyan, 2005, Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by Erlotinib (Tarceva), Cancer Res, 65, 3328, 10.1158/0008-5472.CAN-04-3547 Das, 2006, Non–small cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation, Cancer Res, 66, 9601, 10.1158/0008-5472.CAN-06-2627 Koh, 2012, Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy, Cancer Treat Rev, 38, 626, 10.1016/j.ctrv.2011.11.003 Simone, 2015, Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies, Transl Lung Cancer Res, 4, 545 Wan, 2009, Unexpected high lung toxicity from radiation pneumonitis in a phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non–small-cell lung cancer(NSCLC), Int J Radiat Oncol*Biol*Phys, 75, S110, 10.1016/j.ijrobp.2009.07.267 Bhardwaj, 2016, Molecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinoma, Ann Transl Med, 4, 50 Chung, 2009, In vitro and In vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase, Clin Cancer Res, 15, 3050, 10.1158/1078-0432.CCR-08-2954 Hayes, 2012, Phase II efficacy and pharmacogenomic study of selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements, Clin Cancer Res, 18, 2056, 10.1158/1078-0432.CCR-11-0563 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Green, 1994, Endpoints for multimodal clinical trials in Stage III non-small cell lung cancer (NSCLC): a consensus report, Lung Cancer, 11, S11, 10.1016/0169-5002(94)91859-7 Adizie, 2019, Stage III non-small cell lung cancer management in England, Clin Oncol, 31, 688, 10.1016/j.clon.2019.07.020 Harrow, 2016, The challenges faced in developing novel drug radiation combinations in non-small cell lung cancer, Clin Oncol, 28, 720, 10.1016/j.clon.2016.08.004 Sharma, 2016, Clinical development of new drug–radiotherapy combinations, Nat Rev Clin Oncol, 13, 627, 10.1038/nrclinonc.2016.79 Hallqvist, 2011, Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung Cancer Study Group, Lung Cancer, 71, 166, 10.1016/j.lungcan.2010.05.011 Blumenschein, 2011, Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non–small-cell lung cancer: RTOG 0324, J Clinc Oncol, 29, 2312, 10.1200/JCO.2010.31.7875 Ready, 2010, Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial, J Thoracic Oncol, 5, 1382, 10.1097/JTO.0b013e3181eba657 Rothschild, 2011, Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable Stage III non–small cell lung cancer: a phase I trial, Int J Radiat Oncol*Biol*Phys, 80, 126, 10.1016/j.ijrobp.2010.01.048 Zhao, 2015, A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non–small-cell lung cancer: north central cancer treatment group (NCCTG)-N0321, J Thoracic Oncol, 10, 172, 10.1097/JTO.0000000000000383 Sarkaria, 2007, Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer, J Thoracic Oncol, 2, 751, 10.1097/JTO.0b013e3180cc2587 Deutsch, 2015, Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer, Ann Oncol, 26, 1223, 10.1093/annonc/mdv105 Iacovelli, 2012, Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials, Acta Oncol, 51, 873, 10.3109/0284186X.2012.705019 Bristow, 2018, Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology, Lancet Oncol, 19, e240, 10.1016/S1470-2045(18)30096-2 Sugiyama, 2004, Evaluation of 3'-deoxy-3'-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice, J Nuclear Med, 45, 1754 Ullrich, 2008, Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET), PLoS ONE, 3, 10.1371/journal.pone.0003908 Yeh, 2007, Biological Characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor, Clin Cancer Res, 13, 1576, 10.1158/1078-0432.CCR-06-1150 Davies, 2007, Mol Cancer Ther, 6, 2209, 10.1158/1535-7163.MCT-07-0231 Christodoulou, 2014, Investigation of a Patient Reported Outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer, Radiother Oncol, 112, 244, 10.1016/j.radonc.2014.07.008 Abravan, 2020, Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer, J Thoracic Oncol, 15, 1624, 10.1016/j.jtho.2020.06.008 Tang, 2014, Lymphopenia association with gross tumor volume and lung v5 and its effects on non-small cell lung cancer patient outcomes, Int J Radiat Oncol*Biol*Phys, 89, 1084, 10.1016/j.ijrobp.2014.04.025 Diehl, 2017, Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors, Oncotarget, 8, 114268, 10.18632/oncotarget.23217 Chen, 2020, Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy, Radiother Oncol, 150, 114, 10.1016/j.radonc.2020.05.051 Walls, 2020, CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer, Clin Transl Radiat Oncol, 25, 61, 10.1016/j.ctro.2020.09.006